<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654182</url>
  </required_header>
  <id_info>
    <org_study_id>#2007591-102</org_study_id>
    <nct_id>NCT04654182</nct_id>
  </id_info>
  <brief_title>Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method</brief_title>
  <official_title>Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioScience Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the residual antimicrobial effectiveness of one test product when tested using a&#xD;
      modification of the methodology of the standardized ASTM E115-11 (2017)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Actual">December 24, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial counts</measure>
    <time_frame>at 6 hours</time_frame>
    <description>Average Log reduction in counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial Counts</measure>
    <time_frame>at 12 hours</time_frame>
    <description>Average Log reduction in counts</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hand Hygiene</condition>
  <arm_group>
    <arm_group_label>Log reduction in bacterial count</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>Product used in accordance with manufacturers Hand Hygiene instructions</description>
    <arm_group_label>Log reduction in bacterial count</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects may be of either sex, between the ages of 18 and 65 years, and of any race.&#xD;
&#xD;
          -  Subjects must be able to read and understand English.&#xD;
&#xD;
          -  Subjects must possess both hands and all ten digits.&#xD;
&#xD;
          -  Subjects must have an average baseline population of at least 1.0 x 105 colony forming&#xD;
             units (CFU) per hand.&#xD;
&#xD;
          -  Subjects must have no active skin rashes, dermatoses, hangnails, or breaks in the skin&#xD;
             of the hands or forearms. Subjects must also have no inflammatory skin conditions,&#xD;
             such as dermatitis, eczema, or psoriasis, anywhere on the body.&#xD;
&#xD;
          -  Subjects must be in good general health and have no medical diagnosis of a physical&#xD;
             condition, such as a current or recent severe illness, a heart murmur, mitral valve&#xD;
             prolapse with heart murmur, congenital heart disease, an organ transplant, medicated&#xD;
             or uncontrolled diabetes, hepatitis B, hepatitis C, an immunocompromised condition&#xD;
             such as AIDS (or HIV positive), lupus, fibromyalgia, ulcerative colitis, Crohn's&#xD;
             disease, asthma, heart disease, hypertension, or medicated multiple sclerosis.&#xD;
&#xD;
          -  Subjects must have read and signed the Informed Consent Form, List of Restricted&#xD;
             Products, and Allowed and Restricted Products For Hand Cleaning During Coronavirus&#xD;
             Disease 2019 (COVID-19) Pandemic prior to participating in the study, all located in&#xD;
             the separate Informed Consent documents. Subjects must also have a current&#xD;
             Authorization to Use and Disclose Protected Health Information Form on file at the&#xD;
             testing facility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated in a clinical study in the past 7 days or be currently participating&#xD;
             in another clinical study.&#xD;
&#xD;
          -  Wash the hands or applying lotion within the 2-hour period prior to baseline sampling&#xD;
             or testing.&#xD;
&#xD;
          -  Be experiencing any signs/symptoms of respiratory illness, including cough, fever&#xD;
             (body temperature of ≥ 100.0 °F) or chills, shortness of breath or difficulty&#xD;
             breathing, persistent pain or pressure in the chest, confusion or inability to respond&#xD;
             to external stimuli, bluish lips/face, loss of taste/smell, sore throat, headache,&#xD;
             nasal discharge (&quot;runny nose&quot;), frequent sneezing, or general fatigue / body aches.&#xD;
&#xD;
          -  Have a current diagnosis of active Coronavirus Disease 2019 (COVID-19) or have been in&#xD;
             close contact within the last 2 weeks of anyone who has been diagnosed as having&#xD;
             contracted COVID-19.&#xD;
&#xD;
          -  Have been regularly smoking or vaping over the past 2 years.&#xD;
&#xD;
          -  Have limited mobility or dexterity that would hamper their ability to perform the&#xD;
             study as directed.&#xD;
&#xD;
          -  Have known allergies or sensitivities to latex (rubber), alcohols, sunscreens,&#xD;
             deodorants, laundry detergents, topically applied fragrances, cleansers, soaps,&#xD;
             lotions, or to common antibacterial agents, particularly chlorohexidine gluconate.&#xD;
&#xD;
          -  Have experienced hives (raised welts) as a reaction to anything that contacted the&#xD;
             skin with the exception of plants known to cause reactions for most humans (e.g.,&#xD;
             poison oak or poison ivy).&#xD;
&#xD;
          -  Have a history of anaphylactic shock, anaphylactoid reaction, or anaphylactoid shock.&#xD;
&#xD;
          -  Have a known hypersensitivity to the test product or any of its components, especially&#xD;
             in those with a history of possible chlorhexidine-related allergic reactions.&#xD;
&#xD;
          -  Contact the brain, cerebral membrane, middle ear and eyes with the test product and&#xD;
             such contact must be avoided.&#xD;
&#xD;
          -  Be receiving any antibiotic medications during the 7-day pre-test period through&#xD;
             completion of the study.&#xD;
&#xD;
          -  Be receiving any steroids (including steroid medications used to treat asthma) other&#xD;
             than for contraception, hormone therapy, or menopausal purposes during the 7-day&#xD;
             pre-test period through completion of the study.&#xD;
&#xD;
          -  Have any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).&#xD;
&#xD;
          -  Be nursing a child.&#xD;
&#xD;
          -  Be pregnant, plan to become pregnant or impregnate a sexual partner within the&#xD;
             pre-test and test periods of the study.&#xD;
&#xD;
          -  Have any medical condition or use any medications that, in the opinion of the&#xD;
             Principal Investigator, or Consulting Physician(s) should preclude participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bioscience Laboratories, Inc</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

